<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33663328</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2154-1256</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Small GTPases</Title><ISOAbbreviation>Small GTPases</ISOAbbreviation></Journal><ArticleTitle>The progress in <i>C9orf72</i> research: ALS/FTD pathogenesis, functions and structure.</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>76</EndPage><MedlinePgn>56-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21541248.2021.1892443</ELocationID><Abstract><AbstractText>The hexanucleotide repeat (GGGGCC) expansion in <i>C9orf72</i> is accounted for a large proportion of the genetic amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The hypotheses of how the massive G4C2 repeats in <i>C9orf72</i> destroy the neurons and lead to ALS/FTD are raised and improving. As a multirole player, C9orf72 exerts critical roles in many cellular processes, including autophagy, membrane trafficking, immune response, and so on. Notably, the partners of C9orf72, through which C9orf72 participates in the cell activities, have been identified. Notably, the structures of the C9orf72-SMCR8-WDR41 complex shed light on its activity as GTPase activating proteins (GAP). In this manuscript, we reviewed the latest research progress in the C9orf72-mediated ALS/FTD, the physiological functions of C9orf72, and the putative function models of C9orf72/C9orf72-containing complex.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Urology, State Key Laboratory of Biotherapy, West China Hospital, College of Life Sciences, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tizhong</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8986-438X</Identifier><AffiliationInfo><Affiliation>Department of Urology, State Key Laboratory of Biotherapy, West China Hospital, College of Life Sciences, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Kefeng</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8200-9380</Identifier><AffiliationInfo><Affiliation>Department of Urology, State Key Laboratory of Biotherapy, West China Hospital, College of Life Sciences, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Shiqian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7589-8877</Identifier><AffiliationInfo><Affiliation>Department of Urology, State Key Laboratory of Biotherapy, West China Hospital, College of Life Sciences, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Small GTPases</MedlineTA><NlmUniqueID>101530974</NlmUniqueID><ISSNLinking>2154-1248</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020690">GTPase-Activating Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020690" MajorTopicYN="N">GTPase-Activating Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">DENN domain</Keyword><Keyword MajorTopicYN="N">GAP</Keyword><Keyword MajorTopicYN="N">GEF</Keyword><Keyword MajorTopicYN="N">SMCR8</Keyword><Keyword MajorTopicYN="N">WDR41</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">lysosome</Keyword><Keyword MajorTopicYN="N">mTOR</Keyword><Keyword MajorTopicYN="N">membrane trafficking</Keyword><Keyword MajorTopicYN="N">neurodegenerative</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33663328</ArticleId><ArticleId IdType="pmc">PMC9707547</ArticleId><ArticleId IdType="doi">10.1080/21541248.2021.1892443</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie I, Boeve B, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Jiang J, Gendron TF, et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat Neurosci. 2020;23:615&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24:313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I, Xiang S, Kato M, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature. 2014;507:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="pubmed">24598541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Rothstein JD.. C9ORF72-ALS/FTD: transgenic mice make a come-BAC. Neuron. 2016;90:427&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7045171</ArticleId><ArticleId IdType="pubmed">27151634</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon EG, Lu L, Sharma A, et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. 2016;5: DOI:10.7554/eLife.17820</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.17820</ArticleId><ArticleId IdType="pmc">PMC5050020</ArticleId><ArticleId IdType="pubmed">27623008</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM.. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14:544&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng S-M, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339(6125):1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S, Gronke S, Niccoli T, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, Lu Y, Lopez-Gonzalez R, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Gendron TF, Prudencio M, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science. 2015;348:1151&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692360</ArticleId><ArticleId IdType="pubmed">25977373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci. 2016;19:668&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Zhang P, Kim HJ, et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167:774&#x2013;788 e717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Lehmer C, Martinez-Sanchez A, et al. In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome recruitment. Cell. 2018;172:696&#x2013;705 e612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035389</ArticleId><ArticleId IdType="pubmed">29398115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z, Liu L, Tao Z, et al. Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nat Commun. 2019;10:2906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606620</ArticleId><ArticleId IdType="pubmed">31266945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Xu X, Hao Z, et al. Poly-PR in C9ORF72-related amyotrophic lateral sclerosis/frontotemporal dementia causes neurotoxicity by clathrin-dependent endocytosis. Neurosci Bull. 2019;35:889&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754483</ArticleId><ArticleId IdType="pubmed">31148094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Guo L, Gonzales PK, et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science. 2019;363: DOI:10.1126/science.aav2606</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav2606</ArticleId><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Sundaramoorthy V, Sultana JM, et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet. 2014;23:3579&#x2013;3595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Liang C, Swaminathan K, et al. A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy. Sci Adv. 2016;2:e1601167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010369</ArticleId><ArticleId IdType="pubmed">27617292</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellier C, Campanari ML, Corbier CJ, et al. Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to induce motor neuron dysfunction and cell death. Embo J. 2016;35:1276&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910533</ArticleId><ArticleId IdType="pubmed">27103069</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, Smith EF, Bauer CS, et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. Embo J. 2016;35:1656&#x2013;1676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J, Nayak A, Schaeffer V, et al. Multiplex image-based autophagy RNAi screening identifies SMCR8 as ULK1 kinase activity and gene expression regulator. Elife. 2017;6: DOI:10.7554/eLife.23063</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.23063</ArticleId><ArticleId IdType="pmc">PMC5323046</ArticleId><ArticleId IdType="pubmed">28195531</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Roczniak-Ferguson A, Ferguson SM. C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. Mol Biol Cell. 2016;27:3040&#x2013;3051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5063613</ArticleId><ArticleId IdType="pubmed">27559131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Zhou X, Robins AM, et al. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol Commun. 2016;4:51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4870812</ArticleId><ArticleId IdType="pubmed">27193190</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Burberry A, Wang JY, et al. The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis. Genes Dev. 2018;32:929&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075033</ArticleId><ArticleId IdType="pubmed">29950492</ArticleId></ArticleIdList></Reference><Reference><Citation>Trageser KJ, Smith C, Herman FJ, et al. Mechanisms of immune activation by c9orf72-expansions in amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2019;13:1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6914852</ArticleId><ArticleId IdType="pubmed">31920478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JD, Ichida JK. C9ORF72 protein function and immune dysregulation in amyotrophic lateral sclerosis. Neurosci Lett. 2019;713:134523.</Citation><ArticleIdList><ArticleId IdType="pubmed">31568865</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura S, Gerondopoulos A, Linford A, et al. Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. J Cell Biol. 2010;191:367&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958468</ArticleId><ArticleId IdType="pubmed">20937701</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Bradley MJ, Cai Y, et al. Insights regarding guanine nucleotide exchange from the structure of a DENN-domain protein complexed with its Rab GTPase substrate. Proc Natl Acad Sci U S A. 2011;108:18672&#x2013;18677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219131</ArticleId><ArticleId IdType="pubmed">22065758</ArticleId></ArticleIdList></Reference><Reference><Citation>Marat AL, Dokainish H, McPherson PS. DENN domain proteins: regulators of Rab GTPases. J Biol Chem. 2011;286:13791&#x2013;13800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077579</ArticleId><ArticleId IdType="pubmed">21330364</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Danials RD, Wong LH, et al. Discovery of new Longin and Roadblock domains that form platforms for small GTPases in Ragulator and TRAPP-II. Small GTPases. 2013;4:62&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747258</ArticleId><ArticleId IdType="pubmed">23511850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Iyer LM, He F, et al. Discovery of novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front Genet. 2012;3:283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521125</ArticleId><ArticleId IdType="pubmed">23248642</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TP, Daniels RD, Gatta AT, et al. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics. 2013;29:499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570213</ArticleId><ArticleId IdType="pubmed">23329412</ArticleId></ArticleIdList></Reference><Reference><Citation>Levivier E, Goud B, Souchet M, et al. uDENN, DENN, and dDENN: indissociable domains in Rab and MAP kinases signaling pathways. Biochem Biophys Res Commun. 2001;287:688&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">11563850</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen K, Rogala KB, Chou HT, et al. Cryo-EM structure of the human FLCN-FNIP2-Rag-ragulator complex. Cell. 2019;179:1319&#x2013;1329 e1318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008705</ArticleId><ArticleId IdType="pubmed">31704029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Sheng J, Xu L, et al. Cryo-EM structure of C9ORF72-SMCR8-WDR41 reveals the role as a GAP for Rab8a and Rab11a. Proc Natl Acad Sci U S A. 2020;117:9876&#x2013;9883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211967</ArticleId><ArticleId IdType="pubmed">32303654</ArticleId></ArticleIdList></Reference><Reference><Citation>Su M-Y, Fromm SA, Zoncu R, et al. Structure of the C9orf72 ARF GAP complex that is haploinsufficient in ALS and FTD. Nature. 2020;585:251&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054479</ArticleId><ArticleId IdType="pubmed">32848248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Sheng J, Xu L, et al. The C9orf72-SMCR8-WDR41 complex is a GAP for small GTPases. Autophagy. 2020. DOI:10.1080/15548627.2020.1779473</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2020.1779473</ArticleId><ArticleId IdType="pmc">PMC7469575</ArticleId><ArticleId IdType="pubmed">32521185</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006;7:710&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, et al. Implications for future therapies. Neuron. 2020;108:822&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris SP, Likanje MN, Andrews JA. Amyotrophic lateral sclerosis: update on clinical management. Curr Opin Neurol. 2020;33:641&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">32868602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S242&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">8959996</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:509&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. 2017;14:762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine. A Randomized Trial. 2004;63:1364&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505150</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care. 2018;24:S320-S326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care. 2018;24:S320&#x2013;s326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Al-Chalabi A, Ruddy D, et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain. 2006;129:868&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pubmed">16495328</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita M, Al-Chalabi A, Andersen PM, et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology. 2006;66:839&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421333</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J, Behrends C. Multifaceted role of SMCR8 as autophagy regulator. Small GTPases. 2020;11:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6959302</ArticleId><ArticleId IdType="pubmed">28696821</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler AR, Donnelly CJ, Rothstein JD. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat Rev Neurosci. 2016;17:383&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Burguete AS, Almeida S, Gao FB, et al. GGGGCC microsatellite RNA is neuritically localized, induces branching defects, and perturbs transport granule function. Elife. 2015;4:e08881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4758954</ArticleId><ArticleId IdType="pubmed">26650351</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, et al. Gain of Toxicity from ALS/FTD-linked repeat expansions in C9ORF72 Is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. Disease Mechanisms of C9ORF72 Repeat Expansions. Cold Spring Harb Perspect Med. 2018;8: DOI:10.1101/cshperspect.a024224</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024224</ArticleId><ArticleId IdType="pmc">PMC5880161</ArticleId><ArticleId IdType="pubmed">28130314</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YA, Aristizabal MJ, Lu PY, et al. Genome-wide profiling of yeast DNA:RNA hybrid prone sites with DRIP-chip. PLoS Genet. 2014;10:e1004288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990523</ArticleId><ArticleId IdType="pubmed">24743342</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera A, Garcia-Muse T. R loops: from transcription byproducts to threats to genome stability. Mol Cell. 2012;46:115&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">22541554</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, Liu Y, Banez-Coronel M, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110:E4968&#x2013;4977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Babic Leko M, Zupunski V, Kirincich J, et al. Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion. Behav Neurol. 2019;2019:2909168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350563</ArticleId><ArticleId IdType="pubmed">30774737</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, Mertens J, Boeynaems S, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Lattante S, Ber IL, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol. 2013;74:180&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Rouleau GA, Dion PA, et al. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS One. 2013;8:e83450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861484</ArticleId><ArticleId IdType="pubmed">24349511</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine W, Sun L, Wang KW, et al. Excessive endosomal TLR signaling causes inflammatory disease in mice with defective SMCR8-WDR41-C9ORF72 complex function. Proc Natl Acad Sci U S A. 2018;115:E11523&#x2013;E11531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298088</ArticleId><ArticleId IdType="pubmed">30442666</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Q, Yang M, Liang C, et al. C9orf72 and smcr8 mutant mice reveal MTORC1 activation due to impaired lysosomal degradation and exocytosis. Autophagy. 2019;1&#x2013;16. DOI:10.1080/15548627.2019.1703353</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1703353</ArticleId><ArticleId IdType="pmc">PMC8386604</ArticleId><ArticleId IdType="pubmed">31847700</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, McKeever PM, Lau A, et al. Synaptic localization of C9orf72 regulates post-synaptic glutamate receptor 1 levels. Acta Neuropathol Commun. 2019;7:161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813971</ArticleId><ArticleId IdType="pubmed">31651360</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Leverenz JB, Bekris LM, et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Mazzini L, et al. Extensive genetics of ALS: a population-based study in Italy. Neurology. 2012;79:1983&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484987</ArticleId><ArticleId IdType="pubmed">23100398</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Valdmanis P, Millecamps S, et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78:1519&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">22539580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Tosolini AP, Gordon D, et al. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30:3655&#x2013;3662 e3652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090381</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P, Ho WY, Yen YC, et al. The vulnerability of motor and frontal cortex-dependent behaviors in mice expressing ALS-linked mutation in TDP-43. Neurobiol Aging. 2020;92:43&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">32422502</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieverding K, Ulmer J, Bruno C, et al. Hemizygous deletion of Tbk1 worsens neuromuscular junction pathology in TDP-43(G298S) transgenic mice. Exp Neurol. 2021;335:113496.</Citation><ArticleIdList><ArticleId IdType="pubmed">33038415</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao W, Jeong YH, Lin S, et al. Rodent models of TDP-43: recent advances. Brain Res. 2012;1462:26&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613131</ArticleId><ArticleId IdType="pubmed">22608070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Zago P, Ambrogio AD, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC. Synaptic Paths to Neurodegeneration: the Emerging Role of TDP-43 and FUS in Synaptic Functions. Neural Plast. 2018;2018:8413496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5925147</ArticleId><ArticleId IdType="pubmed">29755516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat. 2013;34:812&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Armakola M, Higgins MJ, Figley MD, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet. 2012;44:1302&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510335</ArticleId><ArticleId IdType="pubmed">23104007</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Zhang YJ, Roberts CM, et al. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet. 2010;19:3206&#x2013;3218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908471</ArticleId><ArticleId IdType="pubmed">20530643</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci. 2010;30:16208&#x2013;16219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3075589</ArticleId><ArticleId IdType="pubmed">21123567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Lin L, Tradewell ML, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2010;19:671&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird AS, Hoecke AV, Muynck LD, et al. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS One. 2010;5:e13368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2954192</ArticleId><ArticleId IdType="pubmed">20967127</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, et al. From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun. 2016;4:70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D, Dafinca R, Scaber J, et al. Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiol Dis. 2019;121:148&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">30290270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer BC, Schuck T, Wheeler JM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119:409&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Good SK, Atkin S, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem. 2010;285:6826&#x2013;6834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825476</ArticleId><ArticleId IdType="pubmed">20040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LS, Cheng WC, Hou SC, et al. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis. 2010;48:56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20014337</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Bareil C, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610&#x2013;2626.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110:E736&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, Gendron TF, Zhang YJ, et al. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci. 2010;30:10851&#x2013;10859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YC, Chiang PM, Tsai KJ. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications. Int J Mol Sci. 2013;14:20079&#x2013;20111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821604</ArticleId><ArticleId IdType="pubmed">24113586</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106:18809&#x2013;18814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, Constable R, So E, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479086</ArticleId><ArticleId IdType="pubmed">26108367</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili MA, Panahi M, Yadav S, et al. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int J Exp Pathol. 2013;94(1):56&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, Bogdanik LP, Tassinari VR, et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141148</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Lin Z, Kim E, et al. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathol Commun. 2019;7:166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819591</ArticleId><ArticleId IdType="pubmed">31661035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein SY, Yagudayeva I, Shneider NA. Mutant TDP-43 causes early-stage dose-dependent motor neuron degeneration in a TARDBP knockin mouse model of ALS. Cell Rep. 2019;26:364&#x2013;373 e364.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Spiller KJ, Ge G, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong L, Lee EB, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121:726&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfieri JA, Pino NS, Igaz LM. Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies. J Neurosci. 2014;34:15244&#x2013;15259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298649</ArticleId><ArticleId IdType="pubmed">25392493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai N, Gitler AD. Yeast screen for modifiers of C9orf72 poly(glycine-arginine) dipeptide repeat toxicity. FEMS Yeast Res. 2018;18: DOI:10.1093/femsyr/foy024</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsyr/foy024</ArticleId><ArticleId IdType="pmc">PMC5946852</ArticleId><ArticleId IdType="pubmed">29528392</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta N, Tsukagoshi S, Hirayanagi K, et al. Suppression of the yeast elongation factor Spt4 ortholog reduces expanded SCA36 GGCCUG repeat aggregation and cytotoxicity. Brain Res. 2019;1711:29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30610877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gois AM, Mendonca DMF, Freire MAM, et al. In vitro and in vivo models of amyotrophic lateral sclerosis: an updated overview. Brain Res Bull. 2020;159:32&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">32247802</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrionero A, Horvitz HR, C9orf72 A. ALS/FTD ortholog acts in endolysosomal degradation and lysosomal homeostasis. Curr Biol. 2018;28:1522&#x2013;1535 e1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">29731301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji YJ, Ugolino J, Zhang T, et al. C9orf72/ALFA-1 controls TFEB/HLH-30-dependent metabolism through dynamic regulation of Rag GTPases. PLoS Genet. 2020;16:e1008738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188304</ArticleId><ArticleId IdType="pubmed">32282804</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuva-Aydemir Y, Almeida S, Gao FB. Insights into C9ORF72-Related ALS/FTD from Drosophila and iPSC Models. Trends Neurosci. 2018;41:457&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015541</ArticleId><ArticleId IdType="pubmed">29729808</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesnicky EC, Wright EG. Drosophila as a model for assessing the function of RNA-binding proteins during neurogenesis and neurological disease. J Dev Biol. 2018;6: DOI:10.3390/jdb6030021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jdb6030021</ArticleId><ArticleId IdType="pmc">PMC6162566</ArticleId><ArticleId IdType="pubmed">30126171</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran H, Almeida S, Moore J, et al. Differential toxicity of nuclear RNA Foci versus dipeptide repeat proteins in a drosophila model of C9ORF72 FTD/ALS. Neuron. 2015;87:1207&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589299</ArticleId><ArticleId IdType="pubmed">26402604</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortier G, Butti Z, Patten SA. Modelling C9orf72-related amyotrophic lateral sclerosis in zebrafish. Biomedicines. 2020;8: DOI:10.3390/biomedicines8100440</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8100440</ArticleId><ArticleId IdType="pmc">PMC7589578</ArticleId><ArticleId IdType="pubmed">33096681</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh TH, Liu HF, Li YW, et al. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp Neurol. 2018;304:114&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">29522758</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten K. GJ. Reduced C9orf72 function leads to defective synaptic vesicle release and neuromuscular dysfunction in zebrafish. Research Square. 2020. DOI:10.21203/rs.3.rs-49118/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-49118/v1</ArticleId><ArticleId IdType="pmc">PMC8233344</ArticleId><ArticleId IdType="pubmed">34172817</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomotto J, Rinkwitz S, Becker TS. Effective heritable gene knockdown in zebrafish using synthetic microRNAs. Nat Commun. 2015;6:7378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468906</ArticleId><ArticleId IdType="pubmed">26051838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, Navakkode S, Liu F, et al. Deregulated expression of a longevity gene, Klotho, in the C9orf72 deletion mice with impaired synaptic plasticity and adult hippocampal neurogenesis. Acta Neuropathol Commun. 2020;8:155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473815</ArticleId><ArticleId IdType="pubmed">32887666</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, Hornburg D, Schludi MH, et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128:485&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrice JR, Gregory-Evans CY, Shaw CA. Animal models of amyotrophic lateral sclerosis: A comparison of model validity. Neural Regen Res. 2018;13:2050&#x2013;2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6199948</ArticleId><ArticleId IdType="pubmed">30323119</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens TG, Partridge L, Isaacs AM. Genetic models of C9orf72: what is toxic? Curr Opin Genet Dev. 2017;44:92&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">28364657</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra R, Lee CW. Mouse models of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis/frontotemporal dementia. Front Cell Neurosci. 2017;11:196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5498553</ArticleId><ArticleId IdType="pubmed">28729824</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, O'Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5:208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin AC, Burr K, Borooah S, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6:5999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, Krishnan G, Rushe M, et al. Production of poly(GA) in C9ORF72 patient motor neurons derived from induced pluripotent stem cells. Acta Neuropathol. 2019;138:1099&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6851345</ArticleId><ArticleId IdType="pubmed">31624870</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursch F, Kalmbach N, Naujock M, et al. Altered calcium dynamics and glutamate receptor properties in iPSC-derived motor neurons from ALS patients with C9orf72, FUS, SOD1 or TDP43 mutations. Hum Mol Genet. 2019;28:2835&#x2013;2850.</Citation><ArticleIdList><ArticleId IdType="pubmed">31108504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, Barbagallo P, Farrimond L, et al. Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS/FTD. Stem Cell Reports. 2020;14:892&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Toro A, T G S, et al. Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD. Mol Neurodegener. 2020;15:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282082</ArticleId><ArticleId IdType="pubmed">32513219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugolino J, Ji YJ, Conchina K, et al. Loss of C9orf72 enhances autophagic activity via deregulated mTOR and TFEB signaling. PLoS Genet. 2016;12:e1006443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119725</ArticleId><ArticleId IdType="pubmed">27875531</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, et al. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep. 2016;6:23204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med. 2016;8:347ra393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Katzman RB, Petrucelli L. ALS and FTD: an epigenetic perspective. Acta Neuropathol. 2016;132:487&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138862</ArticleId><ArticleId IdType="pubmed">27282474</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres BA, Barde Y. Neuronal and glial cell biology. Curr Opin Neurobiol. 2000;10:642&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11084327</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen BK, Schuldi MH, McAvoy K, et al. Synaptic dysfunction induced by glycine-alanine dipeptides in C9orf72-ALS/FTD is rescued by SV2 replenishment. EMBO Mol Med. 2020;12:e10722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7207170</ArticleId><ArticleId IdType="pubmed">32347002</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson RA, Fernandez-Martos CM, Atkin JD, et al. C9ORF72 expression and cellular localization over mouse development. Acta Neuropathol Commun. 2015;3:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4582620</ArticleId><ArticleId IdType="pubmed">26408000</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, Sellier C, Mackenzie IR, et al. Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun. 2018;6:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Yanez A, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Wells MF, Limone F, et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature. 2020;582:89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="pubmed">32483373</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, O'Rourke JG, Yanez A, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585:96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan Y, Sullivan PM, Hu F. SMCR8 negatively regulates AKT and MTORC1 signaling to modulate lysosome biogenesis and tissue homeostasis. Autophagy. 2019;15:871&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526807</ArticleId><ArticleId IdType="pubmed">30696333</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrends C, Sowa ME, Gygi SP, et al. Network organization of the human autophagy system. Nature. 2010;466:68&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901998</ArticleId><ArticleId IdType="pubmed">20562859</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PM, Puente C, Ganley IG, et al. ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy. 2013;9:124&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552878</ArticleId><ArticleId IdType="pubmed">23295650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MG, Hurley JH. Structure and function of the ULK1 complex in autophagy. Curr Opin Cell Biol. 2016;39:61&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828305</ArticleId><ArticleId IdType="pubmed">26921696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, Tai YK, Chang JC, et al. The ALS-FTD-linked gene product, C9orf72, regulates neuronal morphogenesis via autophagy. Autophagy. 2019;15:827&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526867</ArticleId><ArticleId IdType="pubmed">30669939</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Tharkeshwar AK, Amaya C, et al. WDR41 supports lysosomal response to changes in amino acid availability. Mol Biol Cell. 2018;29:2213&#x2013;2227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6249801</ArticleId><ArticleId IdType="pubmed">29995611</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Tharkeshwar AK, Talaia G, et al. PQLC2 recruits the C9orf72 complex to lysosomes in response to cationic amino acid starvation. J Cell Biol. 2020;219: DOI:10.1083/jcb.201906076</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201906076</ArticleId><ArticleId IdType="pmc">PMC7039192</ArticleId><ArticleId IdType="pubmed">31851326</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C, Shao Q, Zhang W, wet al. Smcr8 deficiency disrupts axonal transport-dependent lysosomal function and promotes axonal swellings and gain of toxicity in C9ALS/FTD mouse models. Hum Mol Genet. 2019;28:3940&#x2013;3953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282195</ArticleId><ArticleId IdType="pubmed">31625563</ArticleId></ArticleIdList></Reference><Reference><Citation>Amick J, Ferguson SM. C9orf72: at the intersection of lysosome cell biology and neurodegenerative disease. Traffic. 2017;18:267&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389918</ArticleId><ArticleId IdType="pubmed">28266105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence RE, Fromm SA, Fu Y, et al. Structural mechanism of a Rag GTPase activation checkpoint by the lysosomal folliculin complex. Science. 2019;366:971&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6945816</ArticleId><ArticleId IdType="pubmed">31672913</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigil D, Cherfils J, Rossman KL, et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10:842&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124093</ArticleId><ArticleId IdType="pubmed">21102635</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw RJ. mTOR signaling: RAG GTPases transmit the amino acid signal. Trends Biochem Sci. 2008;33:565&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677387</ArticleId><ArticleId IdType="pubmed">18929489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamber EP, Siedenburg AC, Barr FA. Rab regulation by GEFs and GAPs during membrane traffic. Curr Opin Cell Biol. 2019;59:34&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">30981180</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma Y, Hiragi S, Fukuda M. Rab family of small GTPases: an updated view on their regulation and functions. Febs J. 2020. DOI:10.1111/febs.15453</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15453</ArticleId><ArticleId IdType="pmc">PMC7818423</ArticleId><ArticleId IdType="pubmed">32542850</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller MP, Goody RS. Molecular control of Rab activity by GEFs, GAPs and GDI. Small GTPases. 2018;9:5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902221</ArticleId><ArticleId IdType="pubmed">28055292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiral FR, Kohrs FE, Jin EJ, et al. Rab GTPases and membrane trafficking in neurodegeneration. Curr Biol. 2018;28:R471&#x2013;R486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5965285</ArticleId><ArticleId IdType="pubmed">29689231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsun ZY, Bar-Peled L, Chantranupong L, et al. The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. Mol Cell. 2013;52:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867817</ArticleId><ArticleId IdType="pubmed">24095279</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen K, Huang RK, Brignole EJ, et al. Architecture of the human GATOR1 and GATOR1-Rag GTPases complexes. Nature. 2018;556:64&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5975964</ArticleId><ArticleId IdType="pubmed">29590090</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer S, Subramanian V, Acharya KR. C9orf72, a protein associated with amyotrophic lateral sclerosis (ALS) is a guanine nucleotide exchange factor. PeerJ. 2018;6:e5815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6195791</ArticleId><ArticleId IdType="pubmed">30356970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivadasan R, Hornburg D, Drepper C, et al. C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons. Nat Neurosci. 2016;19:1610&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">27723745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaineau M, Ioannou MS, McPherson PS. Rab35: gEFs, GAPs and effectors. Traffic. 2013;14:1109&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pubmed">23905989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiontke S, Langemeyer L, Kuhlee A, et al. Architecture and mechanism of the late endosomal Rab7-like Ypt7 guanine nucleotide exchange factor complex Mon1-Ccz1. Nat Commun. 2017;8:14034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216073</ArticleId><ArticleId IdType="pubmed">28051187</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 2011;91:119&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710122</ArticleId><ArticleId IdType="pubmed">21248164</ArticleId></ArticleIdList></Reference><Reference><Citation>Petit CS, Roczniak-Ferguson A, Ferguson SM. Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases. J Cell Biol. 2013;202:1107&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787382</ArticleId><ArticleId IdType="pubmed">24081491</ArticleId></ArticleIdList></Reference><Reference><Citation>Nookala RK, Langemeyer L, Pacitto A, et al. Crystal structure of folliculin reveals a hidDENN function in genetically inherited renal cancer. Open Biol. 2012;2:120071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438538</ArticleId><ArticleId IdType="pubmed">22977732</ArticleId></ArticleIdList></Reference><Reference><Citation>De Franceschi N, Wild K, Schlacht A, et al. Longin and GAF domains: structural evolution and adaptation to the subcellular trafficking machinery. Traffic. 2014;15:104&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">24107188</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaia G, Amick J, Ferguson SM. Receptor-like role for PQLC2 amino acid transporter in the lysosomal sensing of cationic amino acids. bioRxiv. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923529</ArticleId><ArticleId IdType="pubmed">33597295</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoe T, Cukierman E, Lee A, et al. The KDEL receptor, ERD2, regulates intracellular traffic by recruiting a GTPase-activating protein for ARF1. Embo J. 1997;16:7305&#x2013;7316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1170331</ArticleId><ArticleId IdType="pubmed">9405360</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Mata R, Szul T, Alvarez C, et al. ADP-ribosylation factor/COPI-dependent events at the endoplasmic reticulum-Golgi interface are regulated by the guanine nucleotide exchange factor GBF1. Mol Biol Cell. 2003;14:2250&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC194875</ArticleId><ArticleId IdType="pubmed">12808027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge L, Melville D, Zhang M, et al. ER-Golgi intermediate compartment is a key membrane source for the LC3 lipidation step of autophagosome biogenesis. Elife. 2013;2:e00947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736544</ArticleId><ArticleId IdType="pubmed">23930225</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang W, Hu F. Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. J Neurochem. 2020. DOI:10.1111/jnc.15255</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15255</ArticleId><ArticleId IdType="pmc">PMC8842544</ArticleId><ArticleId IdType="pubmed">33259633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. Wang H, Tao Z, C9orf72 associates with inactive Rag GTPases and regulates mTORC1-mediated autophagosomal and lysosomal biogenesis. Aging Cell. 2020;19:e13126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189992</ArticleId><ArticleId IdType="pubmed">32100453</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann T, Konig J, Henke C, et al. Solute carrier transporters as potential targets for the treatment of metabolic disease. Pharmacol Rev. 2020;72:343&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">31882442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadley B, Litfin T, Day CJ, et al. Nucleotide sugar transporter SLC35 family structure and function. Comput Struct Biotechnol J. 2019;17:1123&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709370</ArticleId><ArticleId IdType="pubmed">31462968</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang Y, Sun K, et al. SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol. 2019;11:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6359923</ArticleId><ArticleId IdType="pubmed">30239845</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde SR, Maddika S. Post translational modifications of Rab GTPases. Small GTPases. 2018;9:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902199</ArticleId><ArticleId IdType="pubmed">28426288</ArticleId></ArticleIdList></Reference><Reference><Citation>Salaun C, Greaves J, Chamberlain LH. The intracellular dynamic of protein palmitoylation. J Cell Biol. 2010;191:1229&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010063</ArticleId><ArticleId IdType="pubmed">21187327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong E, Peng S, Chandra G, et al. Dynamic palmitoylation links cytosol-membrane shuttling of acyl-protein thioesterase-1 and acyl-protein thioesterase-2 with that of proto-oncogene H-ras product and growth-associated protein-43. J Biol Chem. 2013;288:9112&#x2013;9125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610984</ArticleId><ArticleId IdType="pubmed">23396970</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinnel T, Dian C, Giglione C. Myristoylation, an ancient protein modification mirroring eukaryogenesis and evolution. Trends Biochem Sci. 2020;45:619&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">32305250</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrodinger LLC The PyMOL molecular graphics system, version 1.8 (2015).</Citation></Reference><Reference><Citation>Chi X, Jin X, Chen Y, et al. Structural insights into the gating mechanism of human SLC26A9 mediated by its C-terminal sequence. Cell Discov. 2020;6:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417587</ArticleId><ArticleId IdType="pubmed">32818062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>